rs727505269
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_000138.5(FBN1):c.660delC(p.Cys221ValfsTer109) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. P220P) has been classified as Uncertain significance. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000138.5 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.660delC | p.Cys221ValfsTer109 | frameshift_variant | Exon 7 of 66 | ENST00000316623.10 | NP_000129.3 | |
FBN1 | NM_001406716.1 | c.660delC | p.Cys221ValfsTer109 | frameshift_variant | Exon 6 of 65 | NP_001393645.1 | ||
FBN1 | NM_001406717.1 | c.660delC | p.Cys221ValfsTer78 | frameshift_variant | Exon 7 of 9 | NP_001393646.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.660delC | p.Cys221ValfsTer109 | frameshift_variant | Exon 7 of 66 | 1 | NM_000138.5 | ENSP00000325527.5 | ||
FBN1 | ENST00000559133.6 | n.660delC | non_coding_transcript_exon_variant | Exon 7 of 67 | 1 | ENSP00000453958.2 | ||||
FBN1 | ENST00000674301.2 | n.660delC | non_coding_transcript_exon_variant | Exon 7 of 68 | ENSP00000501333.2 | |||||
FBN1 | ENST00000537463.6 | n.636+24delC | intron_variant | Intron 7 of 30 | 5 | ENSP00000440294.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:1
The p.Cys221fs variant in FBN1 has not been reported in individuals with clinica l features of Marfan syndrome or in large population studies. This variant is pr edicted to cause a frameshift, which alters the protein?s amino acid sequence be ginning at position 221 and leads to a premature termination codon 109 amino aci ds downstream. This alteration is then predicted to lead to a truncated or absen t protein. Heterozygous loss of function of function of the FBN1 gene is an esta blished disease mechanism in Marfan syndrome. In summary, this variant meets our criteria to be classified as pathogenic for Marfan syndrome in an autosomal dom inant manner (http://www.partners.org/personalizedmedicine/LMM). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at